Literature DB >> 4083864

Concentrations of metronidazole and tinidazole in male genital tissues.

J Viitanen, H Haataja, P T Männistö.   

Abstract

The steady-state concentrations of metronidazole and tinidazole in male genital tissues were analyzed in patients subjected to elective gonadal surgery. The nitroimidazoles were administered orally at 500 mg every 8 h, beginning 5 days before the operation. Eight hours after the last dose, the concentrations of tinidazole were 24.1 +/- 2.5 micrograms (mean +/- standard error of the mean)/g of prostatic tissue, 29.1 +/- 2.9 micrograms/g of vas deferens, 22.1 +/- 2.1 micrograms/g of epididymis, and 18.6 +/- 2.3 micrograms/g of testis. The corresponding values of metronidazole were 14.3 +/- 1.8 micrograms/g, 15.9 +/- 1.2 micrograms/g, 14.0 +/- 1.2 micrograms/g, and 12.5 +/- 1.7 micrograms/g, respectively.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4083864      PMCID: PMC180334          DOI: 10.1128/AAC.28.6.812

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Penetration of the blood brain barrier by metronidazole and tinidazole.

Authors:  A M Jokipii; V V Myllylä; E Hokkanen; L Jokipii
Journal:  J Antimicrob Chemother       Date:  1977-05       Impact factor: 5.790

2.  Diffusion of antibiotics from plasma into prostatic fluid.

Authors:  D G Winningham; N J Nemoy; T A Stamey
Journal:  Nature       Date:  1968-07-13       Impact factor: 49.962

3.  The blood-testis barrier: a morphologic or physiologic phenomenon?

Authors:  S S Howards; T T Turner
Journal:  Trans Am Assoc Genitourin Surg       Date:  1978

4.  Concentrations of metronidazole and tinidazole in female reproductive organs after a single intravenous infusion and after repeated oral administration.

Authors:  P Männistö; M Karhunen; J Mattila; O Koskela; A M Suikkari; P Heinonen; R Tuimala; H Haataja
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

5.  Concentrations of metronidazole and tinidazole in abdominal tissues after a single intravenous infusion and repetitive oral administration.

Authors:  J Viitanen; O Auvinen; T Tunturi; P Männistö; H Haataja
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

6.  Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route.

Authors:  J Mattila; P T Männistö; R Mäntylä; S Nykänen; U Lamminsivu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

7.  Determination of metronidazole and misonidazole and their metabolites in plasma and urine by high-performance liquid chromatography.

Authors:  R A Marques; B Stafford; N Flynn; W Sadée
Journal:  J Chromatogr       Date:  1978-07-01

8.  Penetration of metronidazole and tinidazole into the aqueous humor in man.

Authors:  J Mattila; K Nerdrum; H Rouhiainen; P Männistö; E Tuovinen; U Lamminsivu
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

Review 9.  Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-11       Impact factor: 9.546

10.  Serum and tissue tinidazole concentrations after intravenous infusion.

Authors:  J Viitanen; O Auvinen; T Tunturi
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

View more
  8 in total

1.  Penetration of tinidazole into skin blister fluid following its oral administration.

Authors:  A Klimowicz; A Nowak; S Bielecka-Grzela
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial.

Authors:  J R Schwebke; A Rompalo; S Taylor; A C Seña; D H Martin; L M Lopez; S Lensing; J Y Lee
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

4.  Trichomonas vaginalis genital infections: progress and challenges.

Authors:  Laura H Bachmann; Marcia M Hobbs; Arlene C Seña; Jack D Sobel; Jane R Schwebke; John N Krieger; R Scott McClelland; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

5.  Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 20.999

Review 6.  A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.

Authors:  Elissa Meites; Charlotte A Gaydos; Marcia M Hobbs; Patricia Kissinger; Paul Nyirjesy; Jane R Schwebke; W Evan Secor; Jack D Sobel; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

Review 7.  Different Drugs, Same End: Ultrastructural Hallmarks of Autophagy in Pathogenic Protozoa.

Authors:  Yasmin Pedra-Rezende; Isabela S Macedo; Victor Midlej; Rafael M Mariante; Rubem F S Menna-Barreto
Journal:  Front Microbiol       Date:  2022-03-29       Impact factor: 5.640

Review 8.  Recent advances in the epidemiology, diagnosis, and management of Trichomonas vaginalis infection.

Authors:  Olivia T Van Gerwen; Christina A Muzny
Journal:  F1000Res       Date:  2019-09-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.